KR20170116948A - A composition of angelicae gigantis radix, cnidii rhizoma and cinnamomi cortex for treating menopause and partial androgen deficiency in aging male - Google Patents

Abstract

The present invention relates to a composition for improving the symptoms of menopausal symptoms comprising Angelica gigas, Angelica keiskeae, and broiler chickens as active ingredients.
The present invention relates to a pharmaceutical composition containing, as an active ingredient, an extract obtained by mixing Angelica gigas Nakai, Angelica japonica, and broiler chickens at a weight ratio of 1.5 to 2.5: 1: 1 and administering the extract at an amount of 50 to 200 mg / kg / day The present invention relates to a composition having an effect capable of improving symptoms of menopausal symptoms.

Description

TECHNICAL FIELD The present invention relates to a composition for improving the symptoms of menopausal symptoms, comprising Angelica gigas, Angelica keiskei, and broiler chickens as active ingredients. BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for improving the symptoms of menopausal gynecologic diseases,

The present invention relates to a composition for improving the symptoms of menopausal symptoms comprising Angelica gigas, Angelica keiskeae, and broiler chickens as active ingredients.

The present invention relates to a pharmaceutical composition containing, as an active ingredient, an extract obtained by mixing Angelicae gigantis, Angelica gigas, and broiler chickens at a weight ratio of 1.5 to 2.5: 1: 1, and administering it at a dose of 50 to 200 mg / kg / day The present invention relates to a composition having an effect capable of improving symptoms of menopausal symptoms.

In general, climacteric is a kind of endocrine syndrome. It is a transition period in which the overall and gradual decrease of ovarian function occurs and the physiological function and sexual function are reduced or lost. It is a permanent process of menopause, Menopause.

Postmenopausal women may have acute chronic symptoms due to changes in hormones, such as decreased estrogen production, follicular stimulating hormone (FSH), and elevated luteininzing hormone (LH).

Symptoms of these menopausal periods include symptoms due to vascular changes such as hot flush, night sweat, tachycardia or headache, musculoskeletal symptoms such as myalgia, arthralgia and back pain, and urinary frequency or urinary incontinence And several years after the menopausal symptoms such as memory loss, depression, loss of concentration and dizziness symptoms such as dizziness occurs.

Hormone replacement therapy and nonsteroidal remedies have been developed to improve the symptoms of women's menopausal symptoms. Among them, estrogen replacement therapy is known to be the most effective method. However, the use of long-term medicines according to the above-mentioned therapy may cause endometrial cancer, breast cancer, hypertension, thrombosis, gallstone-like stones, and may also cause a mild bleeding, and owing to side effects such as ovarian hyperstimulation, There is a problem that it can not be taken without.

In order to overcome the problems caused by the therapeutic treatment of these drugs, development of an agent for improving female menopausal symptoms based on natural herbal medicine has been attempted.

In addition, men do not have the same menopause as women, but since the age of 40-50, the secretion of male hormones gradually decreases, and the sensitivity of target cells to testosterone also decreases, so that various menopausal symptoms such as women appear.

In addition, since both men and women have lowered bone mineral density due to menopausal symptoms, there is a risk of osteoporosis. Therefore, natural medicines without side effects are more urgent when they are administered for a long time while improving symptoms of menopausal symptoms.

On the other hand, according to the prior patent documents, Korean Patent Registration No. 10-0486365 discloses a composition for improving menopausal symptoms. In summary, the main features of the composition are a mixture of soybean extract and red ginseng extract with Angelica keiskei, Peony root and licorice extract and vitamin. In contrast to the present invention, Angelicae is commonly used, but there is no description about broiler chickens and celestial gods.

Korean Patent Publication No. 2003-0033473 discloses a composition for the treatment of gynecological diseases. In summary, the main features are mixed extracts of Angelica gigas, Angelica keiskei, Baekjaejak, Baekyoung, Byeongryeong, corn mustache, ginseng, health, yulmu, safflower seeds and hwanggi. In contrast to the present invention, the prior art aims at improving the gynecological disease, so that the technical problems and effects are different from each other.

Korean Registered Patent No. 10-0486365 (published on April 29, 2005) Korean Patent Publication No. 2003-0033473 (published on May 1, 2003)

It is an object of the present invention to provide a composition having an effect capable of improving the symptoms of menopausal symptoms using a natural substance.

In particular, it is intended to provide a composition capable of preventing hormone changes and bone calcification that may appear during menopause.

The present invention aims at solving the technical problem by providing a pharmaceutical composition for improving the symptoms of menopausal symptoms containing the mixed extract of Angelicae gigantis, Angelica keiskei, and broiler chickens as an active ingredient.

In the present invention, the mixed extract is an extract obtained by mixing Angelicae gigantis, Angelica gigas, and broiler chickens at a weight ratio of 1.5 to 2.5: 1: 1.

In the present invention, the concentration of the mixed extract is 50 to 200 mg / kg / day on a 5-week-old oral administration basis.

In the present invention, the mixed extract is effective for increasing uterine weight and uterine function layer thickness, for increasing bone density, for decreasing ALP, for decreasing the expression of bone formation biomarker, And an effect of reducing follicle-stimulating hormone and luteinizing hormone.

The present invention aims at solving the technical problem by providing a food composition for improving the symptoms of menopausal symptoms containing the mixed extract of Angelicae gigantis, Angelica keiskei, and broiler chickens as an active ingredient.

The composition according to the present invention has the effect of increasing the uterine weight and the thickness of the endometrial functional layer.

The composition according to the present invention has an effect of increasing bone density.

The compositions according to the present invention have the ability to reduce ALP.

The composition according to the present invention has the effect of reducing bone formation biomarkers BALP, CTX-1 and osteocalcin.

The composition according to the present invention has an effect of increasing blood estrogen.

The composition according to the present invention has the effect of reducing follicle stimulating hormone and luteinizing hormone.

FIGS. 1 and 2 are graphs showing changes in bone mineral density of male rats for 3 months.
3 is a graph showing ALP changes in the male rats.
4 is a diagram showing weight change in an ovariectomized model.
FIG. 5 is a diagram showing uterine weight changes in an ovariectomized model. FIG.
Fig. 6 is a diagram showing changes in endometrial tissues in an ovariectomized model. Fig.
FIGS. 7 and 8 are views showing changes in femoral bone density in an ovariectomy model.
9 is a graph showing the amount of ALP change in the ovariectomy model.
10 is a graph showing BALP, CTX-1 and osteocalcin changes in an ovariectomized model.
11 is a diagram showing changes in blood estrogen in an ovariectomized model.
12 is a graph showing changes in follicle-stimulating hormone and luteinizing hormone in an ovariectomy model.
13 is a diagram showing an estrogen-active performance evaluation.
14 is a diagram showing evaluation of estrogen receptor expression.

Example  1. A pharmaceutical composition comprising a mixed extract of Angelica gigas, Angelica keiskei, and broiler chickens as an active ingredient

In the present invention, an extract obtained by mixing Angelica gigas Nakai, Angelica gigas, and broiler chickens at a weight ratio of 1.5 to 2.5: 1: 1 is used as an active ingredient. For example, a mixture of 50 g of Angelica gigas, 25 g of Angelica gigas and 25 g of broiler chickens were mixed with 10 times 30% ethanol and extracted twice at 85 to 95 ° C for 3 hours. The mixture was filtered and concentrated under reduced pressure at 60 ° C or lower. Dry X can be obtained.

Based on the experimental example of the present invention, an effective concentration is prepared. Preferably, an effective concentration of 50-200 mg / kg / day (5-week-old mouse oral dose) is used. A pharmaceutical additive is added to the pharmaceutical composition such that the effective concentration of the mixed extract is maintained.

Example  2. Health functional food composition containing mixed extract of Angelica gigas, Angelica keiskei, and broiler chickens as an active ingredient

In the present invention, an extract obtained by mixing Angelica gigas Nakai, Angelica gigas, and broiler chickens at a weight ratio of 1.5 to 2.5: 1: 1 is used as an active ingredient. For example, a mixture of 50 g of Angelica gigas, 25 g of Angelica gigas and 25 g of broiler chickens were mixed with 10 times 30% ethanol and extracted twice at 85 to 95 ° C for 3 hours. The mixture was filtered and concentrated under reduced pressure at 60 ° C or lower. Dry X can be obtained.

Based on the experimental example of the present invention, an effective concentration is prepared. Preferably, an effective concentration of 50-200 mg / kg / day (5-week-old mouse oral dose) is used. The food functional additive is added to the functional food composition so that the effective concentration is properly maintained.

Experimental Example  One. Mourning  Animal model to improve the symptoms of menopausal symptoms

[Experimental Method]

(1) Breeding of experimental animals and sample treatment

Five-week-old rats of Sprague-Dawley strain weighing 170g (magnetic) and 120g (male) were divided into two groups: control group, estrogen-treated group and candidate agent (HPC 3, Angelica: ) Were divided into experimental group and 5 male and 5 male, respectively. During the breeding period, AIN-76 feeds (see Table 1 below) in which the vegetable estrogen component was removed from the general diet were freely taken and the distilled water was freely taken. At the same time, the experimental group was administered the candidate drug dissolved in physiological saline, Of physiological saline was orally administered for 3 months, and estrogen-treated group received physiological saline and estrogen at a dose of 10 μg / kg.

Furtherance Normal feed (g / kg) AIN-76 Casein
DL-Methionine
Cornstarch
Sucrose
Cellulose
Soybean Oil
Corn Oil
Salt Mix
Vitamin Mix
Dyetrose
L-Cystine
t-Butylhydroquinone
Choline Bitartrate 200.00
-
397.486
100.00
50.00
70.00
-
35.00
10.00
132.00
3.00
0.014
2.50 200.00
3.00
150.00
500.00
50.00
-
50.00
35.00
10.00
-
-
-
2.00

(2) Measurement of change in bone density

BMD changes of the lumbar and femur were measured at intervals of 4 weeks using an animal bone mineral density measuring device InAlyzer (medikors). BMD of the femur of the femur after the completion of all experiments was measured And the amount of change was measured.

(3) ALP variation measurement

After the completion of all the tests, the degree of induction of ALP was measured using the blood biochemical equipment (7170S, Hitachi, Tokyo, Japan) using the obtained serum.

[Experiment result]

(1) Bone density change

The lumbar BMD of the male rats measured at intervals of 4 weeks for 12 weeks could not observe the difference between the groups according to the administration. However, BMD of 12th femur showed a significant increase in estrogen compared to the control group at 10 μg / kg. HPC 3 200 mg / kg, the candidate drug, also showed a 12-week BMD increase. (See Fig. 1)

At the end of the experiment, BMD of the experimental group was 0.2603 ± 0.0187 and 0.2577 ± 0.0161 g / cm ² , respectively. The BMD of the experimental group was 0.2157 ± 0.198, 0.003 g / cm < ² >). The BMD of the candidate drug, HPC 3, was 0.2511 ± 0.0003 and 0.2569 ± 0.0002 g / cm ² , respectively, indicating a significant increase of 16.4 and 13.02% compared to the control group. (See Fig. 2)

(2) ALP variation measurement

The ALP values measured after 12 weeks of experiment were 87.5 ± 9.57 and 44.0 ± 16.6 U / L, respectively, in the male rat control group, and 37.0 ± 13.36 and 34.2 ± 7.27 U / L in the estrogen 10 μg / , Respectively, indicating a significant reduction of 60.8% and 15.9%, respectively. In the case of the magnetic rats, the HPC 3-treated group showed a significant decrease of 22.5% as compared with the control group at 67.75 ± 12.6 U / L, but no significant difference was observed in the male rats according to administration of HPC 3 (see FIG. 3) )

Experimental Example  2. Efficacy of ovariectomized animal model to improve menopausal symptoms

[Experimental Method]

(1) Ovariectomy and animal breeding

The patient was anesthetized with ketamine (Keara 100 mg / kg) and 2% Xylazine (Rumpun 0.15 ml / kg) and treated with epilation and aseptic treatment (10% povine-iodine scrub followed by 70% alcohol wipe). The ovaries were ligated to the suture chamber and the ovariectomy was performed on both sides. After ovariectomy, the organs were repositioned into the peritoneal cavity and stapled with a suture thread (OVX). In the ovariectomized group (SHAM), the ovary was not removed and the same sham operation was performed with the same stress as the ovariectomy, and the recovery procedure was performed one week after the procedure.

After the ovariectomy, 200 mg / kg of white oyster and 500 mg / kg of candidate HPC 3 were administered to the experimental group. During the feeding period, AIN-76 feed and distilled water were ad libitum. In the experimental group, the candidate drug dissolved in physiological saline was administered at the same time every day, and the same amount of physiological saline was orally administered to the control group for 3 months.

(2) Measurement of change in bone density

BMD changes of the lumbar and femur were measured at intervals of 4 weeks using an animal bone mineral density measuring device InAlyzer (medikors). BMD of the femur of the femur after the completion of all experiments was measured And the amount of change was measured.

(3) ALP variation measurement

After the completion of all the experiments, the degree of induction of ALP was measured using the obtained biochemical equipment (7170S, Hitachi, Tokyo, Japan)

(4) BALP, Collagen type 1, Osteocalcin measurement

After the completion of all the experiments, the serum levels of BALP, collagen type 1, and osteocalcin ELISA were measured for the separated serum according to the manufacturer 's manual.

(5) Estradiol measurement

Orbital vein collection was performed at intervals of 4 weeks to obtain serum. At the end of the experiment, the blood was collected from the abdominal vein after the ether anesthesia, transferred to a heparinized tube, and centrifuged at 2,500 rpm (4 ° C) for 15 minutes to separate the serum. Serum sex hormone levels were measured according to the manufacturer's manual using the Testosterone and Estradiol ELISA kit (ADI-065, 174; Enzo Life Sciences, U.S.A.).

(6) LH / FSH measurement

After the completion of all the experiments, the amount of change was measured using the LH / FSH ELISA kit according to the manufacturer's manual for the separated serum.

(7) Histological examination

After completion of the animal experiment, the obtained ovarian tissue was attached flat on a filter paper, fixed in 4% formalin solution for 4 hours, and then subjected to general tissue treatment, followed by paraffin embedding and cut to a thickness of 5 μm using a tissue- . Tissue sections were treated with alcohol and distilled water using xylene to remove paraffin, and microscopic examination was performed by H & E (Hematoxylin & Eosin) staining for skin tissue observation.

[Experiment result]

(1) Weight change

Ovariectomy showed an increase in body weight (ovx group). On the other hand, SHAM and estrogen treated group showed significant decrease compared with ovariectomized group. No significant differences were observed with the ovariectomized group in the HPC 3 administration group (see Figure 4).

(2) uterine weight and histological changes

Ovariectomy confirmed uterine weight loss (ovx group). On the other hand, the estrogen group showed a significant decrease compared to the ovariectomized group. HPC 3 and Ovariectomized group (Fig. 5). The part of the uterus that is affected by hormones is the endometrial functioning layer, and the uterine thickness is thinned in the ovariectomized group, which is not affected by estrogen. HPC 3 increased the thickness of the uterine endothelial function layer in a dose-dependent manner (see Figure 6)

(3) Bone density change

Bone mineral density changes were observed for 12 weeks. No significant increase was observed until 8th week, but at 12th week, ovariectomized femur (femur) decreased bone density. Femur BMD of the 10 ug / kg estrogen group showed a significant increase. A significant increase in the bone mineral density of the femur due to the high concentration of HPC 3 and of the experimental drug HPC was observed (see FIG. 7).

After the end of the experiment, the femur of the experimental animals was extracted and the bone mineral density was measured. The ovariectomized group (0.2832 ± 0.0210 g / cm ² ) had a 24% reduction in femoral bone density compared to the control group (0.3532 ± 0.0120 g / cm ² ). The BMD of the 10 μg / kg estrogen group was 0.3403 ± 0.3301 g / cm ² , indicating a significant increase of 20% compared with the control group. 0.3201 ± 0.0330 g / cm ² in the case of the old product, Paek Suwon, showed a 13% increase compared to the ovariectomized group. HPC 3, the candidate agent, increased by 0.2893 ± 0.0382, 0.3013 ± 0.0143, and 0.3203 ± 0.0031 g / cm ² , respectively, by 2.1, 6.4, and 13.1% compared to the ovariectomized group, respectively. Among them, a significant increase was observed at 200 mg / kg of HPC 3 (see FIG. 8).

(4) ALP variation measurement

ALP was measured for 0 to 12 weeks at 4-week intervals. From the 1st week of ovariectomy, a significant increase was observed compared to the SHAM group. The estrogen dose of 10 μg / kg showed a level of ALP similar to SHAM after 1 month.

There was a significant decrease in ovariectomized group from 200 mg / kg and HPC 3 100 mg / kg 2 months later. After 3 months of administration, ovariectomized group (89.0 ± 4.0 U / L) was increased by 47.7% compared to SHAM group (46.5 ± 4.0 U / L). On the other hand, in the Ettrogen group, 50.0 ± 1.0 U / L, 43.7% of the serum ALP level was decreased compared to the ovariectomized group. 62.0 ± 4.0 U / L was lower than that of ovariectomized group. Candidate HPC 3 was 7.5, 18.7 and 29.1% for 50 mg / kg (82.4 ± 1.2 U / L), 100 mg / kg (73.5 ± 2.4 U / L) and 200 mg / And a significant decrease from 100 mg / kg (see Fig. 9).

(5) Measurement of osteogenic biomarker expression

BALP, CTX-1, and osteocalcin were measured. (See Fig. 10).

BALP was increased by 47.7% in the ovariectomized group 156.2 ± 10.8 ng / mL compared to the SHAM group (102.0 ± 8.1 ng / mL). On the other hand, there was a decrease of 37.1% in blood BALP level compared with ovariectomized group in Ettrogen treatment group and 98.2 ± 5.2 ng / mL. And 120.9 ± 7.9 ng / mL, respectively, compared to the ovariectomized group. The candidate drug HPC 3 decreased by 2.8, 19.3, 24.7% by the concentration of 50 mg / kg (134.2 ± 2.4 ng / mL), 100 mg / kg (124.5 ± 4.2 ng / mL) and 200 mg / Respectively. Among them, 200 mg / kg showed a significant decrease.

CTX-1 increased by 33.3% in the ovariectomized group 120.0 ± 6.2 ng / mL compared to the SHAM group (80.0 ± 4.3 ng / mL). On the other hand, the ET-treated group had 92.1 ± 1.5 ng / mL, which was 23.3% lower than the ovariectomised group. And 105.2 ± 4.2 ng / mL, respectively, compared to the ovariectomized group. The candidate agent HPC 3 was 1.7, 10.8, and 12.5% for 50 mg / kg (118.3 ± 2.4 ng / mL), 100 mg / kg (107.5 ± 1.2 ng / mL), and 200 mg / Respectively. Among them, 100 and 200 mg / kg showed significant decrease.

Osteocalcin was increased by 28.7% in the ovariectomized group (87.2 ± 8.2 ng / mL) compared to the SHAM group (62.1 ± 4.2 ng / mL). On the other hand, the estrogen group had 65.2 ± 1.4 ng / mL, which was 25.3% lower than the ovariectomized group. And 75.1 ± 5.2 ng / mL, respectively, compared to the ovariectomized group. The candidate agent HPC 3 was 5.2, 13.4, and 18.4% for 50 mg / kg (82.4 ± 2.4 ng / mL), 100 mg / kg (75.4 ± 2.4 ng / mL), and 200 mg / Respectively. Among them, 200 mg / kg showed a significant decrease.

(6) Blood estrogen concentration

Blood estrogen levels were measured for 0 to 12 weeks at 4-week intervals. From the 1st week of ovariectomy, a significant increase was observed compared to the SHAM group. After 1 month of estrogen 10 μg / kg administration, blood estrogen level was similar to that of SHAM. The number of oysters was significantly increased from 3 months after administration. HPC 3 200 mg / kg 2 months after administration showed significant increase compared to ovariectomized group. After 3 months of administration, the ovariectomized group (32.0 ± 2.03 pg / mL) was reduced by 96.2% compared to the SHAM group (62.8 ± 4.03 pg / mL). On the other hand, the estrogen dose was 70.0 ± 4.03 pg / mL, which was 118.6% higher than that of the ovariectomized group. In the case of white pine oyster, 43.03 ± 3.03 pg / mL was reduced by 34.3% compared to ovariectomized group. The candidate agent HPC 3 was 32.7, 31.4, 61.8% for 50 mg / kg (42.4 ± 2.4 pg / mL), 100 mg / kg (43.4 ± 3.4 pg / mL) and 200 mg / , Indicating a significant increase at all concentrations. (See Fig. 11)

(7) Measure serum LH (follicle stimulating hormone) and FSH (luteinizing hormone)

After completion of the experiment, serum was separated to measure follicle stimulating hormone and luteinizing hormone (see FIG. 12).

Follicle stimulating hormone levels were increased by 28.8% in the ovariectomized group (295.4 ± 10.4 ng / mL) compared to the SHAM group (210 ± 4.6 ng / mL). On the other hand, estrogen-treated group had 245.2 ± 6.2 ng / mL, which was lower than that of ovariectomized group by 16.9%. In the case of the original product, white oyster, 262.3 ± 5.0 ng / mL was decreased by 11.1% compared to ovariectomized group. The candidate agent HPC 3 was 1.7, 5.4, and 12.5% for 50 mg / kg (283.4 ± 2.2 ng / mL), 100 mg / kg (267.4 ± 3.4 ng / mL), and 200 mg / Respectively. Among them, 200 mg / kg showed a significant decrease.

Luteinizing hormone levels were increased by 45.2% in the ovariectomized group (114.0 ± 2.0 ng / mL) compared to the SHAM group (62.4 ± 2.1 ng / mL). On the other hand, estrogen administration group had 68.3 ± 5.2 ng / mL, which was 40.1% lower than that of ovariectomized group. In the case of the original product, Paekwoo Ogum was 82.0 ± 2.1 ng / ml, which was 28.1% lower than the ovariectomized group. The candidate agent HPC 3 was 3.3, 14.7, and 31.6% for 50 mg / kg (106.2 ± 2.1 ng / mL), 100 mg / kg (94.2 ± 3.4 ng / mL), and 200 mg / Respectively. Among them, 200 mg / kg showed a significant decrease.

Experimental Example  3. E-screen analysis and estrogen receptor activity assay to confirm estrogenic activity

[Experimental Method]

(1) Cell culture

The medium was replaced every 3-4 days with RPMI 1640 medium supplemented with 10% FBS, 0.01 mg / mL bovine insulin, antibiotics (100 units / mL penicillin, 100 μg / mL streptomycin) did. MDA-MB231 cells were cultured in RPMI 1640 medium supplemented with 10% FBS and antibiotics (100 units / mL penicillin, 100 μg / mL streptomycin) every 4 to 5 days and then subcultured every 6 to 7 days .

(2) Estrogen activity measurement

Measurement of the cell proliferation effect by estrogen activity can be carried out by the method of Soto et al. (1995) (Soto et al., The E-SCREEN assay as a tool to identify estrogens: anupdate on estrogenic enviromental pollutants. ~ 22, 1995). In order to exclude estrogenic activity of MCF-7 and MDA-MB 231 cells, RPMI 1640 medium containing no phenol red containing 10% charcoal treated FBS was used in 96 wells and 2 × 103 cells per well After seeding, the cells were replaced with test medium (RPMI 1640 without phenol-red containing 5% charcoal dextran treated FBS) for 24 hours, and each candidate agent was treated. After the candidate drug treatment, the MTT dye was used to confirm the estrogenic action of the test substance.

(3) human ER reporter assay

To confirm estrogenic activity, a reporter assay was performed on the estrogen receptor. Human ER reporter assay kit from Indigo Bioscience was used to treat the final material for 4 hours and 17-estradiol (1 nM) was used as a positive control. Estradiol acts as a ligand for the estrogen receptor, specifically acting on ERα (Estrogen Receptor α) and ERβ (Estrogen Receptor β). Negative control (corresponding to the (-) group) was added with the same volume of distilled water as the extract.

[Experiment result]

(1) Estrogen activity measurement

The estrogenic activity of the sample was converted to 100% of the cell viability of the control group without any treatment. In the MCF-7 cells in which the estrogen receptor (ER) was intrinsically expressed, 118.3 ± 8.72% of estrogen 0.05 mM was significantly increased in the positive control group. HPC 3 significantly increased cell viability from 25 to 100 μg / mL compared to the control group. In MDA-MB231 without ER expression, the positive control group, estrogen 0.05 mM, was significantly increased by 109.4 ± 7.56%. HPC 3 significantly increased cell viability at 25 and 50 μg / mL compared to the control (see FIG. 13).

(2) Estrogen receptor expression measurement

In the positive control group, estrogen 6.4 pM, ERα was 2.36 ± 0.49% and ERb was 2.93 ± 0.12%. HPC 3 50 and 100 μg / mL treated group showed a significant increase compared to the control group and showed similar activity to estrogen. (See Fig. 14)

Claims (5)

The present invention relates to a pharmaceutical composition for improving the symptoms of menopausal symptoms, which comprises a mixed extract of Angelica gigas, Angelica keiskei, and broiler chickens as an active ingredient.
The method according to claim 1,
Wherein the mixed extract is an extract obtained by mixing Angelicae gigantis, Angelica gigas, and broiler chickens at a weight ratio of 1.5 to 2.5: 1: 1.
The method according to claim 1,
Wherein the concentration of the mixed extract is 50 to 200 mg / kg / day on a 5-week-old oral administration basis.
The method according to claim 1,
The combined extracts can be used to increase the efficacy of increasing uterine weight and uterine function layer thickness, increasing bone density, reducing ALP, reducing the expression of biomarker, enhancing blood estrogen, And a follicle-stimulating hormone and a luteinizing hormone.
The present invention relates to a food composition for improving the symptoms of menopausal symptoms, which comprises a mixed extract of Angelica keiskei, Angelica keiskei, and broiler chickens as an active ingredient.

Images